Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

[1]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Kontoyiannis,et al.  The changing epidemiology of invasive candidiasis , 2008, Cancer.

[3]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  B. Barlogie,et al.  Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications , 2007, Cancer.

[5]  M. Shimizu,et al.  Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. , 2007, Biochemical pharmacology.

[6]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Raoul Herbrecht,et al.  Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  K. Sepkowitz,et al.  Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[10]  T. Buclin,et al.  Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods , 2006, Antimicrobial Agents and Chemotherapy.

[11]  G. Mikus,et al.  Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype , 2006, Antimicrobial Agents and Chemotherapy.

[12]  D. Andes,et al.  Pharmacology of Systemic Antifungal Agents , 2006 .

[13]  A. Warris,et al.  1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. , 2006, The New England journal of medicine.

[14]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[15]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[16]  S. Ogawa,et al.  Prospective Comparison of the Diagnostic Potential of Real-Time PCR, Double-Sandwich Enzyme-Linked Immunosorbent Assay for Galactomannan, and a (1→3)-β-d-Glucan Test in Weekly Screening for Invasive Aspergillosis in Patients with Hematological Disorders , 2004, Journal of Clinical Microbiology.

[17]  A. Sulahian,et al.  False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. , 2003, The New England journal of medicine.

[18]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[20]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[21]  J. Powers,et al.  Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[22]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[23]  H. Tamura,et al.  Determination of plasma (1 → 3)-β-d-glucan: A new diagnostic aid to deep mycosis , 1992 .

[24]  G. Ubeaud‐Séquier,et al.  The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals , 2008, Clinical pharmacokinetics.

[25]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[26]  M. M. Juárez,et al.  Oral versus intravenous therapy in the treatment of systemic mycosis. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  T. Kaminuma,et al.  Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. , 2003, Drug metabolism and pharmacokinetics.

[28]  A. Bernard,et al.  Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.